ABSTRACT
Introduction Adolescents and young adults are at risk of poor adherence to tuberculosis (TB) treatment and subsequently worse TB treatment outcomes. Digital adherence technologies, including the mobile phone-based 99DOTS platform, can support TB treatment, but there is limited data on their use among adolescents.
Objective To evaluate factors associated with the uptake of 99DOTS among adolescents with TB.
Methods We conducted an explanatory sequential mixed methods study that utilized quantitative data from adolescents collected during the scale-up of 99DOTS at 30 health facilities in Uganda, and qualitative in-depth and key informant interviews with a subset of adolescents with pulmonary TB offered 99DOTS and healthcare providers at participating facilities. Findings were further mapped onto the Capability, Opportunity, Motivation, and Behavior (COM-B) model.
Results Overall, 299/410 (73%) eligible adolescents were enrolled in 99DOTS. Older adolescents 15 to 19 years old were more likely to enroll in 99DOTS than younger adolescents 10 to 14 years [aPR= 0.56, 95% CI: (0.42-0.73)]. Conversely, adolescents treated at Health Center IV and General Hospitals were less likely to be enrolled compared to Health Center III (aPR= 0.8, 95% CI, 0.67-0.94, and aPR=0.71, 95% CI 0.58-0.85, respectively). Technological savviness among older adolescents, access to training, caregiver or treatment supporter involvement, and desire for wellness facilitated the uptake of 99DOTS. In contrast, variable mobile phone access, concerns about TB status disclosure, and health worker workload in hospitals were barriers to the uptake of 99DOTS.
Conclusion 99DOTS uptake was high among adolescents with TB. Increased access to mobile phones, health worker training on adolescent communication, and more involvement of caregivers could facilitate greater use of 99DOTS and similar technologies.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Yes
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
1) Makerere University School of Public Health Research and Ethics Committee -Protocol #630 2) Uganda National Council for Science and Technology -HS 2436.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data, that supports the findings of this study are available from the corresponding author. It is available on open science frame work platform. https://osf.io/k2mq6/files/osfstorage/67498957a08e49e00d6facea
https://osf.io/k2mq6/files/osfstorage/67498957a08e49e00d6facea
